Tue , August 14, 2018
Vaporizer
Home / Arizona Marijuana News / Tucson Cannabis Testing Device Company Gets New Investment

Tucson Cannabis Testing Device Company Gets New Investment

Cannabis Testing

Tucson-based PathogenDx, a provider of DNA-based pathogen testing kits for the cannabis, botanical, food and agriculture industries, has received a minority equity investment from Salveo Capital, an alternative investment firm specializing in the legalized cannabis industry.

PathogenDx’s technology offers growers, processors, producers, consumers and ancillary service providers with real-time data and information pertaining to the quality of their product. The technology provides customers with access to accurate real-time answers to determine if their plants or crops have been contaminated with fungi, molds, viruses or mildew.

“With its cutting edge solutions and high quality products, PathogenDx represents an innovative and disruptive company that is changing the testing process for cannabis-related products as we know it,” said Jeffrey Howard, a Managing Partner at Salveo Capital. “We believe that as customers and growers continue to seek the latest and greatest methods to assure the utmost quality and purity in their product, the demand for PathogenDx’s services will continue to rise. We are thrilled to complete this investment and are very much looking forward to partnering with the entire PathogenDx team to drive further value into the business.”

Milan Patel, CEO and Co-Founder of PathogenDx, said, “As we enter into the next phase as a company, it is critical that we have the strategic support in place to provide our customers with the premier products and services they have come to expect in the most simplistic and cost-effective manner. We are confident that Salveo’s investment and operational experience within the cannabis space will promote significant growth, help us expand into new markets, and continue to ensure the safest possible products from a human health standpoint. We are honored to welcome Salveo as an investor and are eager to begin collaborating with their team.”

AP Photo/Jeff Chiu

Share story: